Alvotech

46,50 SEK

+9,93 %

Mindre end 1K følgere

ALVO SDB

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

+9,93 %

-8,82 %

-39,74 %

-57,73 %

-

-

-

-

-52,70 %

Alvotech is a biotechnology company that focuses on the development and manufacture of biosimilar medicines. The company's pipeline consists of biosimilar candidates aimed at treating autoimmune diseases, eye diseases, osteoporosis and cancer. The company offers its products to patients all over the world. Alvotech was founded in 2013 and has its headquarters in Reykjavík.

Markedsværdi

15,1 mia. SEK

Aktieomsætning

784,2 t SEK

Omsætning

5,43 mia.

EBIT %

14,33 %

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mia.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse24.11.2025, 10.30

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Selskabsmeddelelse20.11.2025, 09.00

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Selskabsmeddelelse12.11.2025, 21.40

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse10.11.2025, 09.00

UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)

Selskabsmeddelelse6.11.2025, 14.00

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Selskabsmeddelelse4.11.2025, 21.01

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Selskabsmeddelelse2.11.2025, 22.10

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Selskabsmeddelelse22.10.2025, 09.00

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Selskabsmeddelelse6.10.2025, 08.40

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Selskabsmeddelelse22.9.2025, 10.15

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®

Selskabsmeddelelse22.9.2025, 08.30

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Selskabsmeddelelse19.9.2025, 11.45

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Selskabsmeddelelse4.9.2025, 13.15

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Selskabsmeddelelse21.8.2025, 08.30

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Selskabsmeddelelse20.8.2025, 10.05

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Selskabsmeddelelse13.8.2025, 20.15

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Selskabsmeddelelse6.8.2025, 12.00

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Selskabsmeddelelse10.7.2025, 08.40

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Selskabsmeddelelse9.7.2025, 08.30

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

Selskabsmeddelelse3.7.2025, 23.02

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.